Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7143-7148

  Cline, Edith I ^a   Bicciato, Silvio ^b   DiBello, Carlo ^b   Lingen, Mark W ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID; THROMBOSPONDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LEWIS LUNG; CELLS, CULTURED; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS;

EID: 0037115690     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Folkman, J. Tumor angiogenesis. In: J. Mendelsohn, P. M. Howley, M. A. Israel, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 206-232. Philadelphia: W. B. Saunders, 1995.
2. Kerbel, R. S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000.
3. Brem, H., Gresser, I., Grosfeld, J., and Folkman, J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J. Ped. Surg., 28: 1253-1257, 1993.
4. Lingen, M. W., Polverini, P. J., and Bouck, N. P. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against head and neck squamous cell carcinoma. Cancer Res., 58: 5551-5558, 1998.
5. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K., A. Bigelow, K., Heimann, R., Gately, S., Dhanahal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394: 287-291, 1998.
6. Teicher, B. A. Potentiation of cytotoxic cancer therapies by anti-angiogenic agents. In: B. A. Teicher (ed.), Anti-angiogenic Agents in Cancer Therapy, pp. 277-316. Totowa, NJ: Human Press, Inc., 1999.
7. Minischetti, M., Vacca, A., Ribatti, D., Iurlaro, M., Ria, R., Pellegrino, A., Gasparini, G., and Dammacco, A. F. TNP-470 and recombinant human interferon -alpha2a inhibit angiogenesis synergistically. Br. J. Hematol., 109: 829-837, 2000.
8. Fidler, I. J. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. (Bethesda), 93: 1040-1041, 2001.
9. Filleur, S., Volpert, O. V., Degeorges, A., Voland, C., Reiher, F., Clezardin, P., Bouck, N., and Cabon, F. In vivo mechanisms by which tumors producing thrombospondin I bypass its inhibitory effects. Genes Dev., 15: 1373-1382, 2001.
10. Yu, J. L., Rak. J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science (Wash. DC), 295: 1526-1528, 2002.
11. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 145: 510-514, 1994.
12. Liss, C., Fekete, M. J., Hasina, R., Lam, C. K., and Lingen, M. W. Paracrine angiogenic loop between head and neck squamous cell carcionomas and macrophages. Int. J. Cancer. 93: 781-785, 2001.
13. Beissbarth, T., Fellenberg, K., Brors, B., Arribas-Prat, R., Boer, J., Hauser, N. C., Scheideler, M., Hoheisel, J. D., Schutz, G., Poustka, A., and Vingron, M. Processing and quality control of DNA array hybridization data. Bioinformatics, 16: 1014-1022, 2000.
14. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1999.
15. Lingen, M. W., Polverini, P. J., and Bouck, N. P. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab. Investig., 74: 476-483, 1996.
16. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCullouch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., and Dirix, L. Y. Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation. Eur. J. Cancer, 32A: 2474-2484, 1996.
17. Volpert, O. V., Zaichuk, T., Zhou, W., Reiher, F., Ferguson, T. A., Stuart, P. M., Amin, M., and Bouck, N. P. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium derived factor. Nat. Med., 8: 349-357, 2002.
18. Shichiri, M., and Hirata, Y. Antiangiogenesis signals by endostatin. FASEB J., 15: 1044-1053, 2001.
19. Towbin, J. A., Casey, B., and Belmont, J. The molecular basis of vascular disorders. Am. J. Hum. Genet., 64: 678-684, 1999.
20. Ashkenazi, A., and Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 11: 255-260, 1999.
21. Stegh, A. H., Schickling, O., Ehret, A., Scaffidi, C., Peterhansel, C., Hofmann, T. G., Grummt, I., Krammer, P. H., and Peter, M. E. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J., 17: 5974-5986, 1988.